NCT03838718: RESAR

REtroperitoneal SArcoma Registry: an International Prospective Initiative

Recruiting now Last updated 12 February 2019

What this trial tests

trial in Retroperitoneal Sarcoma in 2,000 participants. Currently enrolling.

Timeline

1 September 2016

Primary endpoint
31 December 2020

31 December 2030

Quick facts

Lead sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	1 September 2016
Primary completion	31 December 2020
Estimated completion	31 December 2030
Sites	22 locations across France, Italy, United Kingdom, Germany, Poland, South Korea, Canada, Slovenia

Conditions studied

• Retroperitoneal Sarcoma — all drugs for Retroperitoneal Sarcoma →

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — full company profile →

Who can join

18 and older, any sex, with Retroperitoneal Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority.

Primary Objectives of this study are:

* to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers.
* patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM).

Secondary Objectives:

* to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS;
* to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy;
* to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR/DM/OS. These may be important biomarkers of disease;
* to utilize collected pathological material for research collaborations.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group.
   Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, et al · · 2021 · cited 168× · PMID 33852100 · DOI 10.1245/s10434-021-09654-z
2. Targetable Pathways in the Treatment of Retroperitoneal Liposarcoma.
   Casadei L, de Faria FCC, Lopez-Aguiar A, Pollock RE, et al · · 2022 · cited 25× · PMID 35326514 · DOI 10.3390/cancers14061362
3. LDH and hemoglobin outperform systemic inflammatory indices as prognostic factors in patients with soft tissue sarcoma undergoing neoadjuvant treatment.
   Berclaz LM, Di Gioia D, Jurinovic V, Völkl M, et al · · 2025 · cited 5× · PMID 40102864 · DOI 10.1186/s12885-025-13889-4
4. Primary pelvic soft tissue sarcomas (PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).
   Fiore M, Sarre-Lazcano C, Smith M, Khan M, et al · · 2024 · cited 4× · PMID 38805374 · DOI 10.1093/bjs/znae128
5. Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter study.
   Tirotta F, Fiore M, Bonvalot S, Strauss D, et al · · 2025 · cited 2× · PMID 40521170 · DOI 10.1016/j.eclinm.2025.103280
6. Global Variations in Patterns of Care for Retroperitoneal Sarcoma.
   Snow H, Fiore M, Xie J, Strauss D, et al · · 2025 · cited 2× · PMID 40519020 · DOI 10.1097/sla.0000000000006791
7. Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis.
   Li X, Dong R, Xiao M, Min L, et al · · 2022 · cited 2× · PMID 36578082 · DOI 10.1186/s13014-022-02159-3
8. Prognosis-oriented molecular subtypes of retroperitoneal liposarcoma.
   Xiao M, Qin D, Li X, Bu F, et al · · 2024 · cited 1× · PMID 39406474 · DOI 10.1002/ctm2.70050